Daytrana is a transdermal patch developed and marketed by Noven Pharmaceuticals, Inc. that was approved in the US by the Food and Drug Administration (FDA) in April 2006. In the literature, Daytrana is most commonly referred to as methylphenidate transdermal system (MTS). Daytrana is approved by the FDA as a once daily treatment in children — ages 6 to 17 — with attention deficit hyperactivity disorder (ADHD). It is mainly prescribed as a second-line treatment for ADHD when traditional oral forms are not well-tolerated or if patients have difficulty with compliance.

Property Value
dbo:abstract
  • Daytrana is a transdermal patch developed and marketed by Noven Pharmaceuticals, Inc. that was approved in the US by the Food and Drug Administration (FDA) in April 2006. In the literature, Daytrana is most commonly referred to as methylphenidate transdermal system (MTS). Daytrana is approved by the FDA as a once daily treatment in children — ages 6 to 17 — with attention deficit hyperactivity disorder (ADHD). It is mainly prescribed as a second-line treatment for ADHD when traditional oral forms are not well-tolerated or if patients have difficulty with compliance. Noven's original FDA submission indicated that it should be used for 12 hours. When the FDA rejected the submission they requested evidence that a shorter time period was safe and effective, Noven provided such evidence and Daytrana was approved for the aforementioned indication over a 9-hour period. (en)
dbo:wikiPageEditLink
dbo:wikiPageExtracted
  • 2019-10-02 17:14:51Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 5619026 (xsd:integer)
dbo:wikiPageLength
  • 3930 (xsd:integer)
dbo:wikiPageModified
  • 2019-10-02 17:08:08Z (xsd:date)
dbo:wikiPageOutDegree
  • 10 (xsd:integer)
dbo:wikiPageRevisionID
  • 919247964 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:wikiPageUsesTemplate
dct:subject
rdf:type
rdfs:comment
  • Daytrana is a transdermal patch developed and marketed by Noven Pharmaceuticals, Inc. that was approved in the US by the Food and Drug Administration (FDA) in April 2006. In the literature, Daytrana is most commonly referred to as methylphenidate transdermal system (MTS). Daytrana is approved by the FDA as a once daily treatment in children — ages 6 to 17 — with attention deficit hyperactivity disorder (ADHD). It is mainly prescribed as a second-line treatment for ADHD when traditional oral forms are not well-tolerated or if patients have difficulty with compliance. (en)
rdfs:label
  • Daytrana (en)
owl:sameAs
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is foaf:primaryTopic of